Patient and family engagement is important for ensuring positive clinical outcomes in schizophrenia, which can affect a patient's insight and judgement, explained John Kane, MD, professor and chairman, department of psychiatry, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, The Zucker Hillside Hospital.
Patient and family engagement is important for ensuring positive clinical outcomes in schizophrenia, which can affect a patient's insight and judgement, explained John Kane, MD, professor and chairman, department of psychiatry, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, The Zucker Hillside Hospital.
TranscriptHow important is patient and family engagement for ensuring medication adherence and other positive clinical outcomes in schizophrenia?
So, patient engagement is key. We really are not going to succeed in helping people with their illness unless they are engaged in treatment, and that’s a big challenge because an illness like schizophrenia can affect insight and judgment. People sometimes don’t appreciate the fact that they are ill, that they’re experiencing an illness. We also know that treatment may require a long time. People might need to stay in treatment to prevent a relapse from occurring.
So, engagement and sustained engagement is really key. And when the illness first begins, that can be one of the biggest challenges—sustained engagement. Particularly if somebody, ironically, is doing well, they feel they no longer need treatment, and in fact those individuals have a lot to lost if they do get sick again. So, that’s a little bit of a paradox, in a way, for some people. It’s hard for them to appreciate the need for prophylactic treatment, even when they’re feeling well.
In terms of the family, that’s extremely important, as well. Particularly in the early phases of the illness, the young person is often still living with the family or very involved with the family. They need to be educated as to the nature of the illness, what’s going on. So, they’re engagement is also very, very important.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More